Fenofibrate, a known PPARα agonist used clinically for the management of dyslipidemia, reduced pro-inflammatory cytokines levels, promoted neutrophil recruitment to the site of infection and augmented bacterial clearance leading to improved survival in a murine model of Salmonella typhimurium-induced sepsis (87). This evidence concerns the gene PPARA and Sepsis.